Identification of human papillomavirus type 16 (HPV16) as the major risk factor for cervical neoplasia, and mass production of DNA free HPV capsids have paved the way to preventive vaccination trials. Design of such trials requires reliable attack rate data.
Determination of (1) HPV16 and (2) cervical neoplasia attack rates in primiparous women. Estimation of actuarial sample sizes for HPV16 vaccination phase IV trials.
A longitudinal cohort study.
Population based Finnish Maternity Cohort (FMC) and Finnish Cancer Registry (FCR) were linked for the identification of two cohorts of primiparous women: (1) a random subsample of the FMC: 1656 women with two pregnancies between 1983-9 or 1990-6 and living in the Helsinki metropolitan area, and (2) all 72,791 primiparous women living in the same area during 1983-94. Attack rate for persistent HPV16 infection (1) was estimated in 1279 seronegative women by proportion of seroconversions between the first and the second pregnancy. Comparable 10 year cumulative incidence rate (CR) of cervical intraepithelial neoplasia grade III and cervical cancer (CIN III+) (2) was estimated based on cases registered at the FCR during 1991-4.
The HPV16 attack rates were 13.8% (
Notes
Cites: N Engl J Med. 1998 Feb 12;338(7):423-89459645
Cites: BMJ. 1997 Sep 13;315(7109):646-99310566
Cites: Lancet. 1987 May 30;1(8544):1247-92884378
Cites: Postgrad Med J. 1987;63 Suppl 2:73-813317362
Cites: Stat Med. 1988 Dec;7(12):1279-883231951
Cites: Sex Transm Dis. 1990 Jan-Mar;17(1):15-92154865
Cites: Int J Cancer. 1993 Apr 1;53(6):919-238386137
Cites: Int J Cancer. 1993 Jun 19;54(4):594-6068514451
Cites: J Natl Cancer Inst. 1994 Apr 6;86(7):494-98133532
Cites: Lancet. 1994 Jun 4;343(8910):1383-57910881
Cites: Curr Top Microbiol Immunol. 1994;186:55-818205846
Cites: Acta Oncol. 1994;33(4):365-98018367
Cites: Int J Cancer. 1995 Jan 27;60(3):377-827530234
Cites: J Gen Virol. 1995 Mar;76 ( Pt 3):529-397897345